Effects and safety considerations of fenelidone in the treatment of cardiovascular diseases
Finerenone (Finerenone), this drug has shown a therapeutic effect on cardiovascular disease in patients with type 2 diabetes and chronic kidney disease. Recent studies have shown that fenelidone not only effectively reduces the risk of major adverse cardiac events, but also reduces all-cause mortality, myocardial infarction, and new hypertensive events.
To further verify the effectiveness and safety of fenelinone in the treatment of cardiovascular disease, researchers conducted a series of meta-analyses, specifically focusing on patients with type 2 diabetes and chronic kidney disease. The analyzes combined data from four eligible studies, covering a total of 13,943 patients.

The results of the study showed that the incidence of major adverse cardiac events was significantly reduced in the patient group treated with fenelidone (relative riskRR: 0.88, 95% confidence interval CI, 0.80-0.96, P=0.003). At the same time, the drug also significantly reduced all-cause mortality (RR: 0.89, 95% CI, 0.80-0.99, P=0.04), myocardial infarction (RR: 0.79, 95% CI, 0.67-0.92, P=0.003) and risk of new-onset hypertension (RR: 0.71, 95% CI, 0.62-0.81, P<0.00001).
It is worth noting that in terms of adverse events, there was no significant difference between the fenelidone group and the placebo group (RR: 1.00, 95%CI, 0.98-1.01, P=0.59). However, the risk of hyperkalemia in patients in the fenelidone group was increased compared with the placebo group (RR: 2.04, 95% CI, 1.80-2.32, P<0.00001). However, it is gratifying that patients taking fenelidone did not experience an increased risk of cerebrovascular events and new-onset atrial fibrillation.
In view of the above research results, doctors should pay special attention to monitoring patients' blood potassium levels when using fenelidone to treat cardiovascular diseases to ensure the safety and effectiveness of the treatment. The drug is highly effective, but possible side effects need to be carefully managed.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)